Haldol im onset of action

There are no well controlled studies with Haldol (haloperidol) in pregnant women. There are reports, however, of cases of limb malformations observed following maternal use of Haldol along with other drugs which have suspected teratogenic potential during the first trimester of pregnancy. Causal relationships were not established in these cases. Since such experience does not exclude the possibility of fetal damage due to Haldol, this drug should be used during pregnancy or in women likely to become pregnant only if the benefit clearly justifies a potential risk to the fetus.

The dose of HALDOL Decanoate 50 or HALDOL Decanoate 100 should be expressed in terms of its haloperidol content. The starting dose of haloperidol decanoate should be based on the patient's age, clinical history, physical condition, and response to previous antipsychotic therapy. The preferred approach to determining the minimum effective dose is to begin with lower initial doses and to adjust the dose upward as needed. For patients previously maintained on low doses of antipsychotics (. up to the equivalent of 10 mg/day oral haloperidol), it is recommended that the initial dose of haloperidol decanoate be 10–15 times the previous daily dose in oral haloperidol equivalents; limited clinical experience suggests that lower initial doses may be adequate.

There are no well controlled studies with HALDOL (haloperidol) in pregnant women. There are reports, however, of cases of limb malformations observed following maternal use of HALDOL along with other drugs which have suspected teratogenic potential during the first trimester of pregnancy. Causal relationships were not established in these cases. Since such experience does not exclude the possibility of fetal damage due to HALDOL, this drug should be used during pregnancy or in women likely to become pregnant only if the benefit clearly justifies a potential risk to the fetus. Infants should not be nursed during drug treatment.

In the examination of a patient with resting tremor, the physician checks for rigidity and bradykinesia by flexing and extending the patient's arms, seeking signs of cogwheel rigidity. Tremor and rigidity may become more pronounced if patients perform voluntary movements with the opposite limb (., the patient draws a circle in the air with the opposite hand). The patient is asked to stand and to walk, thus displaying evidence of difficulty initiating movement, reduced arm swing, or shuffling gait. If PD is suspected, a trial of therapy with a dopaminergic agent such as levodopa-carbidopa (Sinemet) is appropriate. Referral to a neurologist is indicated when patients fail to respond to the medication or demonstrate an atypical presentation.

Haldol im onset of action

haldol im onset of action

In the examination of a patient with resting tremor, the physician checks for rigidity and bradykinesia by flexing and extending the patient's arms, seeking signs of cogwheel rigidity. Tremor and rigidity may become more pronounced if patients perform voluntary movements with the opposite limb (., the patient draws a circle in the air with the opposite hand). The patient is asked to stand and to walk, thus displaying evidence of difficulty initiating movement, reduced arm swing, or shuffling gait. If PD is suspected, a trial of therapy with a dopaminergic agent such as levodopa-carbidopa (Sinemet) is appropriate. Referral to a neurologist is indicated when patients fail to respond to the medication or demonstrate an atypical presentation.

Media:

haldol im onset of actionhaldol im onset of actionhaldol im onset of action